384 related articles for article (PubMed ID: 28419815)
21. Effect of background parenchymal enhancement on breast cancer detection with magnetic resonance imaging.
Telegrafo M; Rella L; Stabile Ianora AA; Angelelli G; Moschetta M
Diagn Interv Imaging; 2016 Mar; 97(3):315-20. PubMed ID: 26970658
[TBL] [Abstract][Full Text] [Related]
22. Background parenchymal enhancement over exam time in patients with and without breast cancer.
Melsaether A; Pujara AC; Elias K; Pysarenko K; Gudi A; Dodelzon K; Babb JS; Gao Y; Moy L
J Magn Reson Imaging; 2017 Jan; 45(1):74-83. PubMed ID: 27285396
[TBL] [Abstract][Full Text] [Related]
23. Newly Diagnosed Breast Cancer: Comparison of Contrast-enhanced Spectral Mammography and Breast MR Imaging in the Evaluation of Extent of Disease.
Lee-Felker SA; Tekchandani L; Thomas M; Gupta E; Andrews-Tang D; Roth A; Sayre J; Rahbar G
Radiology; 2017 Nov; 285(2):389-400. PubMed ID: 28654337
[TBL] [Abstract][Full Text] [Related]
24. Repeated surgeries in invasive lobular breast cancer with preoperative MRI: Role of additional carcinoma in situ and background parenchymal enhancement.
Preibsch H; Richter V; Bahrs SD; Hattermann V; Wietek BM; Bier G; Kloth C; Blumenstock G; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur J Radiol; 2017 May; 90():181-187. PubMed ID: 28583631
[TBL] [Abstract][Full Text] [Related]
25. Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
Park VY; Kim EK; Kim MJ; Moon HJ; Yoon JH
BMC Cancer; 2018 Jan; 18(1):91. PubMed ID: 29357842
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer.
Berg WA; Madsen KS; Schilling K; Tartar M; Pisano ED; Larsen LH; Narayanan D; Kalinyak JE
AJR Am J Roentgenol; 2012 Jan; 198(1):219-32. PubMed ID: 22194501
[TBL] [Abstract][Full Text] [Related]
27. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging.
Schrading S; Kuhl CK
Radiology; 2015 Dec; 277(3):687-96. PubMed ID: 26176656
[TBL] [Abstract][Full Text] [Related]
28. Screening breast MR imaging in women with a history of lobular carcinoma in situ.
Sung JS; Malak SF; Bajaj P; Alis R; Dershaw DD; Morris EA
Radiology; 2011 Nov; 261(2):414-20. PubMed ID: 21900617
[TBL] [Abstract][Full Text] [Related]
29. Tailored breast cancer screening program with microdose mammography, US, and MR Imaging: short-term results of a pilot study in 40-49-year-old women.
Venturini E; Losio C; Panizza P; Rodighiero MG; Fedele I; Tacchini S; Schiani E; Ravelli S; Cristel G; Panzeri MM; De Cobelli F; Del Maschio A
Radiology; 2013 Aug; 268(2):347-55. PubMed ID: 23579052
[TBL] [Abstract][Full Text] [Related]
30. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
32. Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
Dontchos BN; Rahbar H; Partridge SC; Korde LA; Lam DL; Scheel JR; Peacock S; Lehman CD
Radiology; 2015 Aug; 276(2):371-80. PubMed ID: 25965809
[TBL] [Abstract][Full Text] [Related]
33. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.
Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R
Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926
[TBL] [Abstract][Full Text] [Related]
34. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation.
Giess CS; Yeh ED; Raza S; Birdwell RL
Radiographics; 2014; 34(1):234-47. PubMed ID: 24428293
[TBL] [Abstract][Full Text] [Related]
35. Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?
Iacconi C; Galman L; Zheng J; Sacchini V; Sutton EJ; Dershaw D; Morris EA
Radiology; 2016 May; 279(2):378-84. PubMed ID: 26605912
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy.
Cho N; Han W; Han BK; Bae MS; Ko ES; Nam SJ; Chae EY; Lee JW; Kim SH; Kang BJ; Song BJ; Kim EK; Moon HJ; Kim SI; Kim SM; Kang E; Choi Y; Kim HH; Moon WK
JAMA Oncol; 2017 Nov; 3(11):1495-1502. PubMed ID: 28655029
[TBL] [Abstract][Full Text] [Related]
37. Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
Vreemann S; Gubern-Mérida A; Schlooz-Vries MS; Bult P; van Gils CH; Hoogerbrugge N; Karssemeijer N; Mann RM
Radiology; 2018 Feb; 286(2):443-451. PubMed ID: 29040037
[TBL] [Abstract][Full Text] [Related]
38. Cancellation of MR imaging-guided breast biopsy due to lesion nonvisualization: frequency and follow-up.
Brennan SB; Sung JS; Dershaw DD; Liberman L; Morris EA
Radiology; 2011 Oct; 261(1):92-9. PubMed ID: 21852565
[TBL] [Abstract][Full Text] [Related]
39. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions.
Pediconi F; Catalano C; Roselli A; Padula S; Altomari F; Moriconi E; Pronio AM; Kirchin MA; Passariello R
Radiology; 2007 Jun; 243(3):670-80. PubMed ID: 17446524
[TBL] [Abstract][Full Text] [Related]
40. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
